Could a diabetes drug boost rectal cancer treatment?
NCT ID NCT07314528
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a weight-loss medication (a GLP-1 drug) to standard chemo-radiation before surgery helps rectal cancer patients with a high BMI. About 42 participants will either get the drug plus standard treatment or standard treatment alone. Researchers will measure weight loss, tumor response, and survival to see if the drug improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLP-1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Weight-Loss drug change how your body handles alcohol?
- Can a diabetes drug improve joint replacement outcomes?
- Could a Low-Calorie diet and Weight-Loss drug send type 2 diabetes into remission?
- Pausing GLP-1 drugs before colonoscopy: could a One-Week break improve bowel prep?
- Can a gut bacteria transplant help immunotherapy wipe out rectal cancer before surgery?
- Could a week off GLP-1 drugs make endoscopies safer and more effective?